Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione

Transfusion

Volumn 58, Issue 3, 2018, Pages 748-757

  Laughhunn, Andrew ^a   Huang, Yan Jang S ^b   Vanlandingham, Dana L ^b   Lanteri, Marion C ^a   Stassinopoulos, Adonis ^a  

^a CERUS CORPORATION   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; AMUSTALINE; GLUTATHIONE; FUROCOUMARIN DERIVATIVE;

ARTICLE; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; ERYTHROCYTE COUNT; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; NONHUMAN; PLATELET COUNT; ULTRAVIOLET A RADIATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS TITRATION; BLOOD SAFETY; DRUG EFFECT; ERYTHROCYTE; FEMALE; MALE; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION; VIROLOGY;

BLOOD PLATELETS; BLOOD SAFETY; CHIKUNGUNYA VIRUS; ERYTHROCYTES; FEMALE; FUROCOUMARINS; GLUTATHIONE; HUMANS; MALE; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 85040523638     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14442     Document Type: Article

References (48)

1. Sergon K, Yahaya AA, Brown J, et al. Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg 2007;76:1189-93.
2. Rampal SM, Meena H. Neurological complications in chikungunya fever. J Assoc Physicians India 2007;55:765-9.
3. Burt FJ, Rolph MS, Rulli NE, et al. Chikungunya: a re-emerging virus. Lancet 2012;379:662-71.
4. Kraemer MU, Sinka ME, Duda KA, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife 2015;4:e08347.
5. Tsetsarkin K, Higgs S, McGee CE, et al. Infectious clones of chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis 2006;6:325-37.
6. Centers for Disease Control and Prevention (CDC). Chikungunya fever diagnosed among international travelers—United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2006;55:1040-2.
7. Jain M, Rai S, Chakravarti A. Chikungunya: a review. Trop Doct 2008;38:70-1.
8. Kalantri SP, Joshi R, Riley LW. Chikungunya epidemic: an Indian perspective. Natl Med J India 2006;19:315-22.
9. Krastinova E, Quatresous I, Tarantola A. Imported cases of chikungunya in metropolitan France: update to June 2006. Euro Surveill 2006;11:pii 3030.
10. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007;370:1840-6.
11. Grandadam M, Caro V, Plumet S, et al. Chikungunya virus, southeastern France. Emerg Infect Dis 2011;17:910-3.
12. Paty MC, Six C, Charlet F, et al. Large number of imported chikungunya cases in mainland France, 2014: a challenge for surveillance and response. Euro Surveill 2014;19:pii 20856.
13. Kendrick K, Stanek D, Blackmore C; Centers for Disease Control and Prevention. Notes from the field: transmission of chikungunya virus in the continental United States—Florida, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1137.
14. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011;38:19-31.
15. Bandeira AC, Campos GS, Rocha VF, et al. Prolonged shedding of chikungunya virus in semen and urine: a new perspective for diagnosis and implications for transmission. IDCases 2016;6:100-3.
16. Ramachandra RT, Singh KRP, Pavri KM. Laboratory transmission of an Indian strain of chikungunya virus. Curr Sci 1964;33:235-6.
17. Shah KV, Baron S. Laboratory infection with chikungunya virus: a case report. Indian J Med Res 1965;53:610-3.
18. Tomori O, Monath TP, O'Connor EH, et al. Arbovirus infections among laboratory personnel in Ibadan, Nigeria. Am J Trop Med Hyg 1981;30:855-61.
19. Cordel H, Quatresous I, Paquet C, et al. Imported cases of chikungunya in metropolitan France, April 2005–February 2006. Euro Surveill 2006;11:pii 2944.
20. Moro ML, Gagliotti C, Silvi G, et al. Chikungunya virus in North-Eastern Italy: a seroprevalence survey. Am J Trop Med Hyg 2010;82:508-11.
21. Queyriaux B, Simon F, Grandadam M, et al. Clinical burden of chikungunya virus infection. Lancet Infect Dis 2008;8:2-3.
22. Sissoko D, Moendandze A, Malvy D, et al. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. PLoS One 2008;3:e3066.
23. Nakkhara P, Chongsuvivatwong V, Thammapalo S. Risk factors for symptomatic and asymptomatic chikungunya infection. Trans R Soc Trop Med Hyg 2013;107:789-96.
24. Appassakij H, Promwong C, Rujirojindakul P, et al. The risk of blood transfusion-associated chikungunya fever during the 2009 epidemic in Songkhla Province, Thailand. Transfusion 2014;54:1945-52.
25. Simmons G, Brés V, Lu K, et al. High incidence of chikungunya virus and frequency of viremic blood donations during epidemic, Puerto Rico, USA, 2014. Emerg Infect Dis 2016;22:1221-8.
26. Chow A, Her Z, Ong EK, et al. Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 2011;203:149-57.
27. Chiu CY, Bres V, Yu G, et al. Genomic assays for identification of chikungunya virus in blood donors, Puerto Rico, 2014. Emerg Infect Dis 2015;21:1409-13.
28. Petersen LR, Stramer SL, Powers AM. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 2010;24:15-21.
29. Hoad VC, Speers DJ, Keller AJ, et al. First reported case of transfusion-transmitted Ross River virus infection. Med J Aust 2015;202:267-70.
30. Brouard C, Bernillon P, Quatresous I, et al. Estimated risk of chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008;48:1333-41.
31. Soumahoro MK, Boelle PY, Gaũzere BA, et al. The chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study. PLoS Negl Trop Dis 2011;5:e1197.
32. Rasonglés P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009;49:1083-91.
33. Tsetsarkin KA, Sampson-Johannes A, Sawyer L, et al. Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light. Am J Trop Med Hyg 2013;88:1163-9.
34. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
35. Huang YJ, Hsu WW, Higgs S, et al. Temperature tolerance and inactivation of chikungunya virus. Vector Borne Zoonotic Dis 2015;15:674-7.
36. Laughhunn A, Santa Maria F, Broult J, et al. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion 2017;57:779-89.
37. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008;21:123-32.
38. Gallian P, de Lamballerie X, Salez N, et al. Prospective detection of chikungunya virus in blood donors, Caribbean 2014. Blood 2014;123:3679-81.
39. Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013;53:284-90.
40. Musso D, Richard V, Broult J, et al. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014;54:2924-30.
41. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006;46:2038-46.
42. Gay N, Rousset D, Huc P, et al. Epidemie de chikungunya a Saint-Martin: estimation de la seroprevalence, des proportions de patients symptomatiques et asymptomatiques et du recours aux soins, juillet 2014. Le Bulletin De Veille Sanitaire 2014;Sept-Nov:33-6.
43. Yoon IK, Alera MT, Lago CB, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015;9:e0003764.
44. Oei W, Janssen MP, van der Poel CL, et al. Modeling the transmission risk of emerging infectious diseases through blood transfusion. Transfusion 2013;53:1421-8.
45. Faddy HM, Fryk JJ, Prow NA, et al. Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016;56:1548-55.
46. Marks DC, Fryk J, Hobson-Peters J, et al. Zika virus infectivity is reduced following treatment with the Theraflex UVC-platelet ad Theraflex MB-plasma systems (P-258) [abstract]. Special Issue: 27th Regional Congress of the ISBT, Copenhagen, Denmark, June 17-21, 2017. Vox Sang 2017;112(suppl S1);148.
47. Faddy HM, Fryk JJ, Watterson D, et al. Riboflavin and ultraviolet light: impact on dengue virus infectivity. Vox Sang 2016;111:235-41.
48. Faddy HM, Prow NA, Fryk JJ, et al. The effect of riboflavin and ultraviolet light on the infectivity of arboviruses. Transfusion 2015;55:824-31.